Skip to main content

Advertisement

Table 2 Non-BCMA-targeted CAR T clinical trials in multiple myeloma

From: Recent updates on CAR T clinical trials for multiple myeloma

NCT number (reference) Target Phase Dosage Number of patients Responses
NCT02135406 (32) CD19 1 1.1–6.0 × 108 CAR+T cells 10 VGPR: 6; PR: 2; PD: 2
NCT01886976 (34) CD138 1/2 0.44–1.51 × 107 CAR+ T cells/kg 5 SD: 4; PD: 1
NCT00881920 (35) κ light chain 1 0.2–2.0 × 108 CAR+ T cells/m2 16 (7 MM) 4 SD of 7 MM
  1. Abbreviations: BCMA B cell maturation antigen, CAR Chimeric antigen receptor, PD Progressive disease, PR Partial response, VGPR Very good partial response, SD Stable disease, MM Multiple myeloma